biodesix develops and commercializes blood-based molecular diagnostic tests that advance the standard of care in oncology. our diagnostics help patients and their doctors make more informed decisions about treatment based on a patient's unique molecular profile. we're advancing precision medicine by helping physicians provide the right patient with the right treatment at the right time, and move patients to optimal treatment faster. we partner with pharmaceutical companies to develop tests that accelerate pipelines and bring effective therapies to market. our two commercialized tests, veristrat® & genestrat™, offer results in 72 hours. no tissue is required.
Company profile
Ticker
BDSX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
203986492
BDSX stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
16 Apr 24
8-K
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
9 Apr 24
424B5
Prospectus supplement for primary offering
5 Apr 24
424B5
Prospectus supplement for primary offering
5 Apr 24
10-K
2023 FY
Annual report
1 Mar 24
8-K
Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights
1 Mar 24
S-8
Registration of securities for employees
2 Feb 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
20 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Biodesix Announces Third Quarter 2023 Results and Highlights
7 Nov 23
Transcripts
BDSX
Earnings call transcript
2023 Q4
1 Mar 24
BDSX
Earnings call transcript
2023 Q3
7 Nov 23
BDSX
Earnings call transcript
2023 Q2
7 Aug 23
BDSX
Earnings call transcript
2023 Q1
11 May 23
BDSX
Earnings call transcript
2022 Q4
6 Mar 23
BDSX
Earnings call transcript
2022 Q3
6 Nov 22
BDSX
Earnings call transcript
2022 Q2
6 Aug 22
BDSX
Earnings call transcript
2022 Q1
11 May 22
BDSX
Earnings call transcript
2021 Q4
14 Mar 22
BDSX
Earnings call transcript
2021 Q3
15 Nov 21
Latest ownership filings
SC 13D/A
PATIENCE JOHN
9 Apr 24
SC 13D/A
Strobeck Matthew
9 Apr 24
SC 13D/A
Kennedy Lawrence T. Jr
9 Apr 24
SC 13D/A
SCHULER JACK W
9 Apr 24
4
Chris Vazquez
9 Apr 24
4
Matthew Strobeck
9 Apr 24
4
JACK W SCHULER
9 Apr 24
4
Gary Anthony Pestano
9 Apr 24
4
JOHN PATIENCE
9 Apr 24
4
Kieran O'Kane
9 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.93 mm | 19.93 mm | 19.93 mm | 19.93 mm | 19.93 mm | 19.93 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.39 mm | 4.03 mm | 1.28 mm | 1.88 mm |
Cash used (since last report) | n/a | n/a | 15.87 mm | 26.76 mm | 8.49 mm | 12.47 mm |
Cash remaining | n/a | n/a | 4.05 mm | -6.83 mm | 11.43 mm | 7.46 mm |
Runway (months of cash) | n/a | n/a | 1.7 | -1.7 | 8.9 | 4.0 |
Institutional ownership, Q2 2023
58.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 34 |
Opened positions | 4 |
Closed positions | 5 |
Increased positions | 10 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 14.55 bn |
Total shares | 56.86 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Schuler Jack W | 19.95 mm | $25.94 mm |
Kennedy Lawrence T. Jr | 9.15 mm | $18.76 mm |
Hirschman Orin | 5.57 mm | $7.24 mm |
AIGH Capital Management | 5.06 mm | $6.23 bn |
Patience John | 4.55 mm | $5.92 mm |
Manlia | 3.65 mm | $4.75 mm |
Life Sciences Alternative Funding | 2.19 mm | $44.16 mm |
Vanguard | 1.29 mm | $1.59 bn |
Worth Venture Partners | 1.26 mm | $1.55 bn |
Essex Investment Management | 1.03 mm | $1.27 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Robin Harper Cowie | Series A Non-Voting Convertible Preferred Stock Common Stock | Grant | Acquire A | No | No | 46 | 327 | 15.04 k | 327 |
5 Apr 24 | Scott Hutton | Series A Non-Voting Convertible Preferred Stock Common Stock | Grant | Acquire A | No | No | 46 | 653 | 30.04 k | 653 |
5 Apr 24 | Kennedy Lawrence T. Jr | Series A Non-Voting Convertible Preferred Stock Common Stock | Grant | Acquire A | Yes | No | 46 | 65,218 | 3.00 mm | 65,218 |
5 Apr 24 | Kennedy Lawrence T. Jr | Series A Non-Voting Convertible Preferred Stock Common Stock | Grant | Acquire A | Yes | No | 46 | 43,478 | 2.00 mm | 43,478 |
5 Apr 24 | Kieran O'Kane | Series A Non-Voting Convertible Preferred Stock Common Stock | Grant | Acquire A | No | No | 46 | 327 | 15.04 k | 327 |
5 Apr 24 | Gary Anthony Pestano | Series A Non-Voting Convertible Preferred Stock Common Stock | Grant | Acquire A | No | No | 46 | 22 | 1.01 k | 22 |
News
Biodesix Plans To Present New Data On Liquid Biopsy Technologies At AACR 2024 Annual Meeting
9 Apr 24
S&P 500 Gains Over 1%; GCT Semiconductor Shares Spike Higher
5 Apr 24
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
5 Apr 24
Gold Surges Over 1%; Biodesix Shares Plummet
5 Apr 24
Dow Jumps Over 100 Points; US Economy Adds 303,000 Jobs In March
5 Apr 24
Press releases
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
9 Apr 24
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
5 Apr 24
Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
25 Mar 24
Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights
1 Mar 24
Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference
26 Feb 24